Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects.

Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Philips S, Hilligoss J, Hall SD.

Clin Pharmacol Ther. 2007 Nov;82(5):579-85. Epub 2007 Apr 18. Erratum in: Clin Pharmacol Ther. 2010 Jul;88(1):138. Phillips, S [corrected to Philips, S].

PMID:
17443134
2.

Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects.

Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY.

Clin Pharmacol Ther. 2006 Dec;80(6):646-56.

PMID:
17178265
3.

Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.

Mouly SJ, Matheny C, Paine MF, Smith G, Lamba J, Lamba V, Pusek SN, Schuetz EG, Stewart PW, Watkins PB.

Clin Pharmacol Ther. 2005 Dec;78(6):605-18.

PMID:
16338276
4.

Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.

Pinto AG, Wang YH, Chalasani N, Skaar T, Kolwankar D, Gorski JC, Liangpunsakul S, Hamman MA, Arefayene M, Hall SD.

Clin Pharmacol Ther. 2005 Mar;77(3):178-88.

PMID:
15735612
5.

Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states.

Yu KS, Cho JY, Jang IJ, Hong KS, Chung JY, Kim JR, Lim HS, Oh DS, Yi SY, Liu KH, Shin JG, Shin SG.

Clin Pharmacol Ther. 2004 Aug;76(2):104-12.

PMID:
15289787
6.

CYP3A5 genotype has a dose-dependent effect on ABT-773 plasma levels.

Katz DA, Grimm DR, Cassar SC, Gentile MC, Ye X, Rieser MJ, Gordon EF, Polzin JE, Gustavson LE, Driscoll RM, O'dea RF, Williams LA, Bukofzer S.

Clin Pharmacol Ther. 2004 Jun;75(6):516-28.

PMID:
15179406
7.

Effect of cytochrome P450 3A5*3 genotype on the stereoselective pharmacokinetics of amlodipine in healthy subjects.

Kim KA, Park PW, Park JY.

Chirality. 2009 May;21(5):485-91. doi: 10.1002/chir.20588.

PMID:
18752284
8.

The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients.

Yates CR, Zhang W, Song P, Li S, Gaber AO, Kotb M, Honaker MR, Alloway RR, Meibohm B.

J Clin Pharmacol. 2003 Jun;43(6):555-64.

PMID:
12817518
9.

Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.

Kharasch ED, Walker A, Isoherranen N, Hoffer C, Sheffels P, Thummel K, Whittington D, Ensign D.

Clin Pharmacol Ther. 2007 Oct;82(4):410-26. Epub 2007 Jun 6.

PMID:
17554244
10.

Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine.

Guo LQ, Chen QY, Wang X, Liu YX, Chu XM, Cao XM, Li JH, Yamazoe Y.

Curr Drug Metab. 2007 Aug;8(6):623-30.

PMID:
17691921
11.

Genotype-phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women.

Floyd MD, Gervasini G, Masica AL, Mayo G, George AL Jr, Bhat K, Kim RB, Wilkinson GR.

Pharmacogenetics. 2003 Oct;13(10):595-606.

PMID:
14515058
12.

Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation.

Hu YF, Qiu W, Liu ZQ, Zhu LJ, Liu ZQ, Tu JH, Wang D, Li Z, He J, Zhong GP, Zhou G, Zhou HH.

Clin Exp Pharmacol Physiol. 2006 Nov;33(11):1093-8.

PMID:
17042920
13.

Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem.

Yamamoto T, Kubota T, Ozeki T, Sawada M, Yokota S, Yamada Y, Kumagai Y, Iga T.

Clin Chim Acta. 2005 Dec;362(1-2):147-54. Epub 2005 Jul 15.

PMID:
16024008
14.

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.

Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS.

CMAJ. 2006 Jun 6;174(12):1715-22. Erratum in: CMAJ. 2006 Jul 4;175(1):64.

15.

Effects of grapefruit juice and smoking on verapamil concentrations in steady state.

Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib AH.

Eur J Clin Pharmacol. 2002 Apr;58(1):45-53. Epub 2002 Mar 15.

PMID:
11956673
16.

Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers.

Ho PC, Ghose K, Saville D, Wanwimolruk S.

Eur J Clin Pharmacol. 2000 Dec;56(9-10):693-8.

PMID:
11214778
17.

CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects.

Min DI, Ellingrod VL, Marsh S, McLeod H.

Ther Drug Monit. 2004 Oct;26(5):524-8.

PMID:
15385835
18.

Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil.

Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA.

Clin Pharmacol Ther. 2007 Mar;81(3):386-91.

PMID:
17339868
19.

Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects.

Kim KA, Park PW, Lee OJ, Kang DK, Park JY.

J Clin Pharmacol. 2007 Jan;47(1):87-93.

PMID:
17192506
20.

Gender-specific effects on verapamil pharmacokinetics and pharmacodynamics in humans.

Krecic-Shepard ME, Barnas CR, Slimko J, Jones MP, Schwartz JB.

J Clin Pharmacol. 2000 Mar;40(3):219-30.

PMID:
10709150

Supplemental Content

Support Center